Growing instances of breast cancers among huge women population is propelling demand for the effective therapeutic portfolio across the globe. Technological advancement has improved screening along with the in effective cancer treatments fuelling the market growth. Increasing adoption of enhanced therapeutics is including the blockage of estrogens for the tumour cells reducing the risk of further cell development.
The Global Breast Cancer Therapeutics Market is expected to be around US$ 22 billion by 2028 at a CAGR 8%.
Late menopause, first child birth at late age and early menarche are among key factors responsible for rising provenances of breast cancers in women. Moreover, busy life style is major factors for increasing cases of overweight among women, avoiding the health problems, shorter breast-feeding period. Higher cost of diagnosis at early stages and lack of awareness in several countries may hamper the market growth during the forecast period.
Global breast cancer therapeutics market is segmented based on the product as, hormone drugs, chemotherapy drugs, targeted drug therapy. On the basis of distribution channel the global breast cancer therapeutics market is segregated as hospitals, ambulatory surgical centers, clinics, e-commerce, retail pharmacies. E-commerce is expected to witness notable gains in the forecast years.
Global breast cancer therapeutics market report covers various regions including North America, Europe, Asia Pacific, and Rest of World. The regional breast cancer therapeutics market is further bifurcated for major countries including U.S., Canada, Germany, UK, France, Italy, China, India, Japan, Brazil, South Africa and others.
Competitive Rivalry
Global breast cancer therapeutics market share consists of several players including Teva Pharmaceutical Industries, Puma Biotechnology, GlaxoSmithKline, Roche Diagnostics, AstraZeneca, Novartis, Eli Lilly, Sanofi, Pfizer, and Eisai.
The Breast Cancer Therapeutics Market has been segmented as below:
Breast Cancer Therapeutics Market, By Product
Breast Cancer Therapeutics Market, By Application
Breast Cancer Therapeutics Market, By Region
The report covers:
Report scope:
The global breast cancer therapeutics market report covers detailed study with the underlying influencing factors for the variations in the industry growth trends.
The report scope includes market analysis on regional as well as country level. The report also provides competitive landscape covering company market shares with detailed profiling for major revenue contributing companies.
The report covers a detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Teva Pharmaceutical Industries, Puma Biotechnology, GlaxoSmithKline, Roche Diagnostics, AstraZeneca, Novartis, Eli Lilly, Sanofi, Pfizer, and Eisai.
Reasons to Buy this Report:
Customization:
Customized report as per the requirement can be offered with appropriate recommendations
Below are our new reports:
Digital Multi-Channel ECG Machine Market
1. Introduction
1.1. Key Points
1.2. Report Description
1.3. Markets Covered
1.4. Stakeholders
2. Research Methodology
2.1. Research Scope
2.2. Research Methodology
2.2.1. Market Research Process
2.2.2. Research Methodology
2.2.2.1. Secondary Research
2.2.2.2. Primary Research
2.2.2.3. Models for Estimation
2.3. Market Size Estimation
2.3.1. Bottom-Up Approach
2.3.2. Top-Down Approach
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Drivers
4.2.1. Driver 1
4.2.2. Driver 2
4.2.3. Driver 3
4.3. Restraints
4.3.1. Restraint 1
4.3.2. Restraint 2
4.4. Opportunities
4.4.1. Opportunity 1
4.4.2. Opportunity 2
4.5. Challenges
4.5.1. Challenge 1
4.5.2. Challenge 2
5. Breast Cancer Therapeutics Market, By Product
5.1. Key Points
5.2. Hormone Drugs
5.3. Chemotherapy Drugs
5.4. Targeted Drug Therapy
6. Breast Cancer Therapeutics Market, Distribution Channel
6.1. Key Points
6.2. Hospitals,
6.3. Ambulatory Surgical Centers
6.4. Clinics
6.5. E-Commerce
6.6. Retail Pharmacies
7. Competitive Landscape
7.1. Introduction
7.2. Recent Developments
7.2.1. Mergers & Acquisitions
7.2.2. New Product Developments
7.2.3. Portfolio/Production Capacity Expansions
7.2.4. Joint Ventures, Collaborations, Partnerships & Agreements
7.2.5. Others
8. Company Profile
8.1. Teva Pharmaceutical Industries
8.1.1. Company Overview
8.1.2. Product/Service Landscape
8.1.3. Financial Overview
8.1.4. Recent Developments
8.2. Puma Biotechnology
8.2.1. Company Overview
8.2.2. Product/Service Landscape
8.2.3. Financial Overview
8.2.4. Recent Developments
8.3. GlaxoSmithKline
8.3.1. Company Overview
8.3.2. Product/Service Landscape
8.3.3. Financial Overview
8.3.4. Recent Developments
8.4. Roche Diagnostics
8.4.1. Company Overview
8.4.2. Product/Service Landscape
8.4.3. Financial Overview
8.4.4. Recent Developments
8.5. AstraZeneca
8.5.1. Company Overview
8.5.2. Product/Service Landscape
8.5.3. Financial Overview
8.5.4. Recent Developments
8.6. Novartis
8.6.1. Company Overview
8.6.2. Product/Service Landscape
8.6.3. Financial Overview
8.6.4. Recent Developments
8.7. Eli Lilly
8.7.1. Company Overview
8.7.2. Product/Service Landscape
8.7.3. Financial Overview
8.7.4. Recent Developments
8.8. Sanofi
8.8.1. Company Overview
8.8.2. Product/Service Landscape
8.8.3. Financial Overview
8.8.4. Recent Developments
8.9. Pfizer
8.9.1. Company Overview
8.9.2. Product/Service Landscape
8.9.3. Financial Overview
8.9.4. Recent Developments
8.10. Eisai
8.10.1. Company Overview
8.10.2. Product/Service Landscape
8.10.3. Financial Overview
8.10.4. Recent Developments
The Breast Cancer Therapeutics Market has been segmented as below:
Breast Cancer Therapeutics Market, By Product
Breast Cancer Therapeutics Market, By Application
Breast Cancer Therapeutics Market, By Region
SUBSCRIBE TO OUR NEWSLETTERS
